HIGH

Zydus Lifesciences Chlorpromazine Hydrochloride 25 mg 100-count Tablets Recalled Nationwide (2025)

Zydus Lifesciences Ltd. recalled Chlorpromazine Hydrochloride tablets, 25 mg, 100-count bottles distributed nationwide by Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534. The recall cites CGMP deviations and the presence of N-Nitroso Desmethyl Chlorpromazine above the acceptable intake limit. Stop using the product and contact your healthcare provider or Zydus Pharmaceuticals (USA) Inc. for

Quick Facts at a Glance

Recall Date
September 3, 2025
Hazard Level
HIGH
Brands
Chlorpromazine Hydrochloride, Zydus Lifesciences, Zydus Pharmaceuticals
Category
Health & Personal Care
Sold At
Multiple Retailers
Geographic Scope
1 states
At-Risk Groups
GENERAL

Hazard Information

CGMP Deviations: presence of N-Nitroso Desmethyl Chlorpromazine above the recommended acceptable intake limit

What You Should Do

Consumers and healthcare providers should stop using this product immediately. Contact Zydus Pharmaceuticals (USA) Inc or your healthcare provider for guidance. Notification method: N/A

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

About This Product

Chlorpromazine hydrochloride is an antipsychotic medication used to treat certain psychiatric conditions. It is prescribed by healthcare providers and distributed nationally in the United States.

Why This Is Dangerous

The recall is due to CGMP deviations and the presence of an impurity above acceptable intake limits, which could pose health risks with exposure.

Industry Context

This recall is not described as part of a broader industry pattern in the provided notice.

Real-World Impact

For patients currently using this medication, stopping therapy should be done under clinician guidance to avoid withdrawal or symptom recurrence.

Practical Guidance

How to identify if yours is affected

  1. Check the bottle label for NDC 70710-1130-1
  2. Confirm 100-count bottle size and Rx-only status
  3. Verify the distribution country as the USA
  4. Refer to the FDA recall page for the official recall number D-0632-2025

Where to find product info

FDA recall enforcement page for D-0632-2025 and the manufacturer communications

What timeline to expect

Refunds or replacements typically 4-6 weeks after submission

If the manufacturer is unresponsive

  • Escalate with your pharmacist or clinician
  • Submit complaints to FDA recall page if the company is unresponsive
  • Keep copies of all correspondence and receipts

How to prevent similar issues

  • Verify NDCs before dispensing any prescription drug
  • Ask for manufacturer recall notices when starting therapy
  • Consult your clinician before stopping medications without guidance

Documentation advice

Keep bottle, packaging, receipts, and any recall notices; document dates, conversations, and actions taken

Product Details

NDC: 70710-1130-1; 25 mg tablets; 100-count bottles; Rx only; Manufactured by Zydus Lifesciences Ltd., Baddi, India; Distributed by Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534; Nationwide distribution in the USA; Recall date: 2025-09-03; Status: ACTIVE; Reason: CGMP Deviations: N-Nitroso Desmethyl Chlorpromazine above acceptable intake; Model numbers not specified.

Reported Incidents

No injuries or incidents have been reported.

Key Facts

  • NDC 70710-1130-1
  • 100-count bottle
  • Rx only
  • Manufactured in India
  • Distributed nationwide in the USA
  • CGMP deviations cited

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
8/ 10
Affected Groups
GENERAL
Injury Types
POISONING

Product Details

Model Numbers
Z305060
Z305061
Z306323
Z401153
Z403015
+2 more
UPC Codes
70710-1129
70710-1130
70710-1131
+12 more
Affected States
ALL
Report Date
September 17, 2025
Source Agency
FDA - Drug Safety
Recall Status
ACTIVE

Related Recalls

Vehicles & Parts
HIGH

Mazda CX-70 Recall 2025 for Powertrain Control Module Software May Lose Drive Power

Mazda North American Operations is recalling 2024 CX-90 and 2025 CX-70 SUVs sold through Mazda dealers. The PCM and ECM software can illuminate malfunction indicator lights and cause a loss of drive power, increasing crash risk. Owner notification letters were mailed December 19, 2024, and Mazda will reprogram the PCM and ECM at no charge.

Mazda
Loss of
Read more
Vehicles & Parts
HIGH

Nissan Kicks 2025 Certification Label Recall for GVWR/GAWR Errors (PD136, PMA47)

Nissan North America is recalling certain 2025 Nissan Kicks vehicles sold through Nissan dealers nationwide. The certification label may print incorrect GVWR and GAWR values, risking overload. Some SR trims with a 19-inch wheel package may display an incorrect wheel size on the label, and owners should contact their Nissan dealer to arrange replacement labels.

Nissan
An overloaded
Read more